← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	975	+10	+1%	$45.9B
2	2 Danaher DHR $158B	966	-4	-0.4%	$48.5B
3	3 Novartis NVS $279B	945	+5	+0.5%	$23.2B
4	4 Illumina ILMN $41B	569	+8	+1%	$30.5B
5	5 Agilent Technologies A $49.1B	561	+22	+4%	$10.7B
6	6 Regeneron Pharmaceuticals REGN $80.1B	541	+32	+6%	$37.7B
7	7 Ionis Pharmaceuticals IONS $7.1B	353	+14	+4%	$5.72B
8	8 Revvity RVTY $17B	306	-9	-3%	$5.6B
9	9 Alnylam Pharmaceuticals ALNY $30B	278	+40	+17%	$7.86B
10	10 Charles River Laboratories CRL $14.4B	261	+2	+0.8%	$3.28B
11	11 DELISTED bluebird bio BLUE	235	+25	+12%	$5.88B
12	12 Myriad Genetics MYGN $397M	235	-17	-7%	$3.17B
13	13 Precigen PGEN $2.64B	173	+19	+12%	$4.63B
14	14 Bruker BRKR $8.47B	159	-9	-5%	$2.42B
15	15 DELISTED SANGAMO THERAPEUTICS INC SGMO	156	-15	-9%	$561M
16	16 PTC Therapeutics PTCT $4.98B	155	-2	-1%	$1.57B
17	17 Ultragenyx Pharmaceutical RARE $1.47B	151	+25	+20%	$3.33B
18	18 DELISTED CATALENT, INC. CTLT	149	+31	+26%	$3.53B
19	ISEE 19 DELISTED IVERIC bio, Inc. Common Stock ISEE	139	+10	+8%	$1.59B
20	20 Sarepta Therapeutics SRPT $1.78B	130	+16	+14%	$811M
21	21 Azenta AZTA $1.63B	128	-3	-2%	$729M
22	22 Standard BioTools LAB $248M	107	+3	+3%	$751M
23	23 Pacific Biosciences PACB $619M	102	+8	+9%	$246M
24	24 DELISTED Adverum Biotechnologies ADVM	96	-17	-15%	$256M
25	25 Arrowhead Research ARWR $8.25B	94	+6	+7%	$194M